Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Advances analyze discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, w